Announced today, the Vall d’Hebron Institute of Oncology – Bioinfogate collaboration will validate the utility of the OFF-X translational safety intelligence portal in the design of novel clinical trials, including first-in-human studies
The Vall d’Hebron Institute of Oncology (VHIO) and Bioinfogate have launched a collaborative agreement to analyze new opportunities in optimizing safety assessment and minimizing patient risk in oncology clinical trials. This partnership will seek to establish how integrating preclinical toxicity and clinical safety intelligence facilitates a translational research approach and increases understanding of the safety profile of new treatments.
The agreement involves the use of publicly available information published in Bioinfogate’s OFF-X translational safety intelligence portal to more quickly and precisely identify potential adverse events resulting from treatment with new therapies that are either about to enter clinical trials or are under current clinical development.
A first milestone of the collaboration will be to assess the value of the new OFF-X Evidence Score system to identify the degree of association between targets/drugs and adverse effects in the corpus of more than 320,000 alerts available in OFF-X.
Throughout this collaboration, VHIO will bring its renowned expertise and know-how in pioneering early clinical drug development to evaluate and advise on newly introduced functionalities of the OFF-X platform. These efforts focus on advancing and accelerating the development of more effective and safer anti-cancer therapies, set firmly within the context of precision medicine in oncology.
“Only by factoring in important preclinical insights into clinical study design will we be better equipped to predict, ameliorate and alleviate side effects experienced by patients participating in clinical trials, now and in the future,” commented Elena Garralda, Director of VHIO’s Research Unit for Molecular Therapy of Cancer (UITM) – “la Caixa”, and Principal Investigator of its Early Clinical Drug Development.
“Toxicity and safety assessment represent, along with a deeper understanding of disease processes, next generation experimental models and biomarkers, one of the cornerstones of finding and developing new anticancer therapies. We are very pleased to partner with VHIO, a leading research organization in the field, to demonstrate the usefulness of OFF-X in the clinical setting,” commented Josep Prous, Jr., Executive Director, Bioinfogate.
For more information about VHIO’s participation in this collaboration please contact Amanda Wren, Director of Communications, Vall d’Hebron Institute of Oncology (VHIO), Tel.: +34 932 543 450, Email: firstname.lastname@example.org.
About Bioinfogate OFF-X™
Bioinfogate, a leading data science organization, is the producer of the OFF-X translational safety intelligence portal (www.targetsafety.info). By delivering critical integrated preclinical toxicity and clinical adverse event intelligence coupled to advanced analytics, Bioinfogate OFF-X™ allows safety liabilities to be monitored and anticipated across all phases of drug R&D. Updated daily with expertly curated safety alerts, as of May 2019, the portal covers a range of 7,700 targets and more than 9,500 drugs & biologics, and is populated with more than 320,000 alerts associated to 5,000 adverse effects. OFF-X covers targets and drugs in all stages of drug R&D development from emerging and first-in-class targets to drugs that have reached the marketplace. OFF-X aims to promptly identify toxicology & safety signals and de-risk R&D programs.